Equa Tops February Detailing Ranking in GP, HP Markets, Driven by Expanded Concurrent Use: Rep Track Survey

Novartis Pharma’s diabetes treatment Equa (vildagliptin), which recently obtained expanded concurrent-use indications, was the most promoted drug both in the GP (99 beds or less) and hospital (HP) (100 beds or more) markets in February, a survey conducted by research...read more